Healthcare Services

Global Chronic Pulmonary Hypertension Treatment Market Set for Strong Expansion Reaching $9.33 Billion by 2030 at 5.3% CAGR

March 31, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Chronic Pulmonary Hypertension Treatment Market By The End Of 2030?

The chronic pulmonary hypertension treatment market size has experienced strong growth in recent years. It is projected to expand from $7.19 billion in 2025 to $7.59 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.6%. Historically, this expansion has been driven by the increasing prevalence of cardiovascular and respiratory disorders, heightened awareness of pulmonary hypertension, broader availability of oral PDE-5 inhibitors, the expansion of specialty treatment centers, and a greater use of diagnostic imaging.

The chronic pulmonary hypertension treatment market size is anticipated to experience robust expansion in the coming years, with projections indicating a rise to $9.34 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This growth during the forecast period is primarily driven by increasing approvals of novel PH drugs, rising investment in rare disease therapies, growing adoption of inhalational drug delivery, expansion of telemedicine-based disease management, and an increasing focus on patient-centric care models. Significant trends expected in the forecast period encompass increasing adoption of targeted pulmonary hypertension drugs, a rising use of combination therapy regimens, a growing focus on early diagnosis and disease monitoring, expansion of home-based oxygen and supportive therapies, and an enhanced emphasis on personalized treatment protocols.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21148&type=smp

What Primary Drivers Are Shaping The Development Of The Chronic Pulmonary Hypertension Treatment Market?

The increasing prevalence of cardiovascular diseases is anticipated to fuel expansion in the chronic pulmonary hypertension treatment market. These diseases encompass various conditions impacting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. This significant burden stems from risk factors like poor diets, lack of physical activity, smoking, heavy alcohol intake, obesity, hypertension, diabetes, and an aging demographic. Treatment for chronic pulmonary hypertension aids cardiovascular well-being by decreasing pulmonary artery pressure, improving cardiac function, and diminishing the likelihood of heart failure and associated issues. For example, the National Institutes of Health, a US-based government agency, reported in August 2025 that between 2025 and 2050, cardiovascular prevalence is forecast to climb by 90%, mortality by 73%, and DALYs by 55%, with fatalities increasing from 20.5 million to 35.6 million. Consequently, the substantial impact of cardiovascular diseases is a primary catalyst for the growth of the chronic pulmonary hypertension treatment market.

Which Segment Classifications Shape The Chronic Pulmonary Hypertension Treatment Market?

The chronic pulmonary hypertension treatment market covered in this report is segmented –

1) By Drug Type: Endothelin Receptor Antagonists, Phosphodiesterase (PDE-5) Inhibitors, Prostacyclin Analogs, Soluble Guanylate Cyclase (SGC) Stimulators

2) By Route Of Administration: Oral, Intravenous Or Subcutaneous, Inhalational

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Endothelin Receptor Antagonists: Bosentan, Ambrisentan, Macitentan

2) By Phosphodiesterase (PDE-5) Inhibitors: Sildenafil, Tadalafil, Vardenafil

3) By Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost

4) By Soluble Guanylate Cyclase (SGC) Stimulators: Riociguat

Which Trends Are Influencing The Chronic Pulmonary Hypertension Treatment Market?

Major companies operating in the chronic pulmonary hypertension treatment market are prioritizing innovative solutions, such as subcutaneous injection, to enhance patient compliance, improve convenience, and provide more targeted treatment options. Subcutaneous injection continuously delivers medication beneath the skin, assisting in lowering pulmonary artery pressure and improving blood flow for pulmonary hypertension patients. For instance, in March 2024, Merck & Co Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Winrevair (sotatercept-csrk), signifying a major advancement in pulmonary arterial hypertension (PAH) treatment. This innovative therapy provides unique benefits, distinguishing it as a groundbreaking option for PAH. Clinical trials have shown that Winrevair improves WHO functional class in 29% of patients, compared to 14% in the placebo group, thereby leading to an overall enhancement in quality of life.

Which Companies Are Expanding Their Footprint In The Chronic Pulmonary Hypertension Treatment Market?

Major companies operating in the chronic pulmonary hypertension treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi SA, AstraZeneca PLC, Novartis AG, GSK (GlaxoSmithKline), Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Insmed, Cereno Scientific, Roivant Sciences, LGM Pharma, Liquidia Technologies

Read the full chronic pulmonary hypertension treatment market report here:

https://www.thebusinessresearchcompany.com/report/chronic-pulmonary-hypertension-treatment-global-market-report

How Does The Chronic Pulmonary Hypertension Treatment Market Perform Across Major Global Regions?

North America was the largest region in the chronic pulmonary hypertension treatment market in 2025. The regions covered in the chronic pulmonary hypertension treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Chronic Pulmonary Hypertension Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21148&type=smp

Browse Through More Reports Similar to the Global Chronic Pulmonary Hypertension Treatment Market 2026, By The Business Research Company

Pruritus Therapeutic Global Market Report

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report

Gout Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/gout-therapeutics-global-market-report

Drugs For Benign Prostatic Hypertrophy Global Market Report

https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795